Evidence map›Paper›PMID 33781507›Full record

ReviewNeurosurgery clinics of North America2021

Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.

Dagoberto Estevez-Ordonez, Gustavo Chagoya, Arsalaan Salehani, Travis J Atchley, Nicholas M B Laskay, Matthew S Parr, Galal A Elsayed, Anil K Mahavadi, Sage P Rahm, Gregory K Friedman and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurosurgery clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Cell and gene therapy in neuro-oncology.Handbook of clinical neurology · 2024
    Review
  6. Review
  7. Article
  8. Gene Therapy for High Grade Glioma: The Clinical Experience.Expert opinion on biological therapy · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Dagoberto Estevez-OrdonezDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Gustavo ChagoyaDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Arsalaan SalehaniDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Travis J AtchleyDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Nicholas M B LaskayDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Matthew S ParrDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Galal A ElsayedDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Anil K MahavadiDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Sage P RahmDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Gregory K FriedmanDepartment of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA; Department of Pediatrics, Division of Pediatric Hematology-Oncology, The University of Alabama at Birmingham.
James M MarkertDepartment of Neurosurgery, Neurosurgery, Pediatrics, and Cell, Developmental and Integrative Biology, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA. Electronic address: jmarkert@uabmc.edu.
University of Alabama at Birmingham · US

Funding

Vanderbilt-Emory-Cornell-Duke Global Health Fellowship Consortium-Expanding Diversity for Global Equity (EDGE)D43TW009337 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, HEIMBURGER, DOUGLAS CORBETT · 2017 to 2021
$6.3M
Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor)R25TW009337 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEIMBURGER, DOUGLAS CORBETT, VERMUND, STEN H. · 2012 to 2016
$6.3M
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma PatientsR01CA222903 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CASSADY, KEVIN A, MARKERT, JAMES M · 2018 to 2020
$1.7M
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.R01CA217179 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GILLESPIE, G. YANCEY, MARKERT, JAMES M · 2017 to 2019
$1.6M
UAB Research Education Program for Residents and Fellows in NeuroscienceR25NS079188 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STANDAERT, DAVID G. · 2012 to 2022
$1.1M
Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18.R01FD006368 · FDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GREGORY K FRIEDMAN · 2019 to 2026
$750k
Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14)R01FD005379 · FDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRIEDMAN, GREGORY K · 2016 to 2018
$750k
FDA HHS R01 FD005379FDA HHS R01 FD006368FIC NIH HHS D43 TW009337FIC NIH HHS R25 TW009337NCI NIH HHS R01 CA217179NCI NIH HHS R01 CA222903NINDS NIH HHS R25 NS079188
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) represents one of the most challenging malignancies due to many factors including invasiveness, heterogeneity, and an immunosuppressive microenvironment. Current treatment modalities have resulted in only modest effect on outcomes. The development of viral vectors for oncolytic immunovirotherapy and targeted drug delivery represents a promising therapeutic prospect for GBM and other brain tumors. A host of genetically engineered viruses, herpes simplex virus, poliovirus, measles, and others, have been described and are at various stages of clinical development. Herein we provide a review of the advances and current state of oncolytic virotherapy for the targeted treatment of GBM and malignant gliomas.

Indexed as

Brain NeoplasmsGlioblastomaGliomaOncolytic VirotherapyHumansSimplexvirusTumor MicroenvironmentBrain tumorsGlioblastomaHerpes simplex virus (HSV-1)ImmunovirotherapyOncolytic virotherapyOncolytic virus

Identifiers

PMID33781507
PMCPMC8519502
OpenAlexW3132764055

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.